佐力藥業(300181.SZ)業績快報：2020年淨利升243.70%至8796.29萬元
格隆匯3月9日丨佐力藥業(300181.SZ)披露2020年度業績快報，報吿期內，公司營業收入10.91億元，同比增長19.73%；營業利潤1.09億元，同比增長270.58%；利潤總額1.08億元，同比增長271.75%；歸屬於上市公司股東的淨利潤8796.29萬元，同比增長243.70%。上述業績指標變動的原因主要為：
1、報吿期內，儘管受到一季度疫情的不利影響，但公司積極面對外部環境的變化，聚焦主業，用好核心產品烏靈膠囊、百令片、靈澤片進入國家基本藥物目錄的優勢，穩自營，強招商，加大市場投入和終端醫療機構開發覆蓋，截止2020年12月底，烏靈膠囊在銷醫院(包括三級醫院、二級醫院、一級及其他醫院)數量達到9984家，百令片在銷醫院數量達到3128家，靈澤片在銷醫院數量達到929家。烏靈膠囊作為治療焦慮抑鬱狀態及失眠的基礎用藥，已經獲得中華醫學會、中國醫師協會等頒發的28個臨牀指南、專家共識的推薦；
2、報吿期內，公司主營業務收入穩步增長，烏靈系列營業收入同比增長24.71%，百令系列營業收入同比增長18.80%，隨着公司產能逐步釋放，成本逐漸降低，規模效應得以體現；
3、報吿期內，公司孫公司浙江佐力創新醫療投資管理有限公司參股公司CARsgen Therapeutics Holdings Limited(科濟藥業)估值提升，根據《企業會計準則第 22 號—金融工具確認和計量》的規定，增加該報吿期內公司權益份額約2.05億元，對該報吿期利潤無影響；
4、報吿期內，預計非經常性損益對歸屬於上市公司股東淨利潤的影響金額約為405萬元。
報吿期末，公司總資產為24.52億元，較期初增長19.55%；歸屬於上市公司股東的所有者權益為15.91億元，較期初增長21.43%；每股淨資產為2.6144元，較期初增長21.43%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
